Q-omics provides the consensus-scored PPP1R15A profile across patient tissues and cancer cell-line models. PPP1R15A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, PPP1R15A is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PPP1R15A RNA expression shows 17,328 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, LUAD, and ACC as cancer lineages where PPP1R15A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R15A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R15A survival associations across molecular data types. PPP1R15A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R15A RNA expression–survival associations across cancer types. High PPP1R15A expression shows unfavorable associations in LGG, MESO, ESCA, ACC and OV, but favorable associations in UCEC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for PPP1R15A RNA expression.
This table summarizes PPP1R15A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPP1R15A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R15A shows lower tumor expression in LUAD, BLCA, THCA, LUSC and UCEC and higher tumor expression in KIRC. The LUAD box plot shows higher PPP1R15A RNA expression in normal versus tumor tissue (log2 FC = −1.933, t-test p < 0.001).
This table shows molecular features associated with PPP1R15A in patient tissues and cancer cell lines. In patient samples, PPP1R15A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R15A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
